{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,2]],"date-time":"2025-12-02T18:42:36Z","timestamp":1764700956368,"version":"build-2065373602"},"reference-count":20,"publisher":"MDPI AG","issue":"5","license":[{"start":{"date-parts":[[2022,4,30]],"date-time":"2022-04-30T00:00:00Z","timestamp":1651276800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Antibiotics"],"abstract":"<jats:p>The optimal dosage of cefoperazone-sulbactam for patients with chronic kidney disease (CKD) remains unclear. This study aimed to investigate two treatment strategies of cefoperazone-sulbactam\u20132 g\/2 g twice daily and adjusted dose according to renal function for patients with CKD. A total of 155 patients with CKD received cefoperazone-sulbactam either at a dose of 2 g\/2 g twice daily (study group) or adjusted according to renal function (control group) for the treatment of acute bacterial infection. The primary outcome was the clinical response rate at day 14 and the secondary outcomes included treatment failure and all-cause death. The study group had a higher clinical response rate (80.0% vs. 65.0%) and a lower treatment failure rate (4.0% vs. 23.8%) as compared with the control group. Further multivariable analysis showed that compared with the control group, the study group had a higher clinical response rate (adjusted OR = 4.02; 95% CI, 1.49\u201310.81) and lower treatment failure rate (adjusted OR = 0.06; 95% CI, 0.01\u20130.28). In addition, no significant difference in all-cause mortality was observed between the study and the control group (adjusted OR = 1.95; 95% CI, 0.57\u20136.66). Finally, no significant difference was observed between the study and the control group in the risk of the adverse events (AEs)\u2013diarrhea (p = 0.326), eosinophilia (p = 1.000), prolonged PT (p = 0.674), alteration in renal function (p = 0.938) and leukopenia (n = 0.938). In conclusion, cefoperazone-sulbactam at a dose of 2 g\/2 g twice daily could achieve better clinical efficacy than the reduced dosage regimen. Additionally, this dosage did not increase the risk of AE compared to the reduced dose. Therefore, cefoperazone-sulbactam at a dose of 2 g\/2 g twice daily is an effective and safe regimen for acute bacterial infection in patients with CKD.<\/jats:p>","DOI":"10.3390\/antibiotics11050610","type":"journal-article","created":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T06:23:08Z","timestamp":1651386188000},"page":"610","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Optimal Dose of Cefoperazone-Sulbactam for Acute Bacterial Infection in Patients with Chronic Kidney Disease"],"prefix":"10.3390","volume":"11","author":[{"given":"Chien-Ming","family":"Chao","sequence":"first","affiliation":[{"name":"Department of Intensive Care Medicine, Chi Mei Medical Center, Liouying, Tainan 73657, Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6334-2388","authenticated-orcid":false,"given":"Chih-Cheng","family":"Lai","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Kaohsiung Veterans General Hospital, Tainan Branch, Tainan 710, Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chen-Hsiang","family":"Lee","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Department of Internal Medicine, Kaohsiung Chang Gung Memorial Hospital, Kaohsiung 833, Taiwan"},{"name":"College of Medicine, Chang Gung University, Kaohsiung 833, Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hung-Jen","family":"Tang","sequence":"additional","affiliation":[{"name":"Department of Medicine, Chi Mei Medical Center, Tainan 71004, Taiwan"},{"name":"Department of Medical Research, Chi Mei Medical Center, Tainan 71004, Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2022,4,30]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.ijid.2019.11.006","article-title":"Antimicrobial activity of cefoperazone-sulbactam tested against Gram-Negative organisms from Europe, Asia-Pacific, and Latin America","volume":"91","author":"Sader","year":"2020","journal-title":"Int. J. Infect. Dis."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"2041","DOI":"10.1007\/s10096-014-2175-y","article-title":"Trends in the susceptibility of commonly encountered clinically significant anaerobes and susceptibilities of blood isolates of anaerobes to 16 antimicrobial agents, including fidaxomicin and rifaximin, 2008\u20132012, northern Taiwan","volume":"33","author":"Wang","year":"2014","journal-title":"Eur. J. Clin. Microbiol. Infect. Dis."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1016\/j.jmii.2015.08.024","article-title":"Comparison of commonly used antimicrobial susceptibility testing methods for evaluating susceptibilities of clinical isolates of Enterobacteriaceae and nonfermentative Gram-negative bacilli to cefoperazone-sulbactam","volume":"50","author":"Jean","year":"2017","journal-title":"J. Microbiol. Immunol. Infect."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"229","DOI":"10.4103\/1011-4564.196365","article-title":"Antimicrobial activities of cefoperazone-sulbactam in comparison to cefoperazone against clinical organisms from medical centers in Taiwan","volume":"36","author":"Chiang","year":"2016","journal-title":"J. Med. Sci."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.jmii.2017.08.026","article-title":"The impact of inoculum size on the activity of cefoperazone-sulbactam against multidrug resistant organisms","volume":"51","author":"Chang","year":"2018","journal-title":"J. Microbiol. Immunol. Infect."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"25","DOI":"10.2147\/IDR.S181201","article-title":"In vitro activity of cefoperazone and cefoperazone-sulbactam against carbapenem-resistant Acinetobacter baumannii and Pseudomonas aeruginosa","volume":"12","author":"Lai","year":"2019","journal-title":"Infect. Drug Resist."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.2147\/IDR.S175257","article-title":"Appropriate composites of cefoperazone-sulbactam against multidrug-resistant organisms","volume":"11","author":"Lai","year":"2018","journal-title":"Infect. Drug Resist."},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Sheu, M.J., Chen, C.C., Lu, Y.C., Su, B.A., Zhang, C.C., Wang, S.S., Chuang, Y.C., Tang, H.J., and Lai, C.C. (2020). In Vitro Antimicrobial Activity of Various Cefoperazone\/Sulbactam Products. Antibiotics, 9.","DOI":"10.3390\/antibiotics9020077"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1093\/jac\/dkab018","article-title":"Molecular characteristics and in vitro effects of antimicrobial combinations on planktonic and biofilm forms of Elizabethkingia anophelis","volume":"76","author":"Tang","year":"2021","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"2251","DOI":"10.2147\/IDR.S313828","article-title":"Clinical Efficacy of Cefoperazone-Sulbactam versus Piperacillin-Tazobactam in the Treatment of Hospital-Acquired Pneumonia and Ventilator-Associated Pneumonia","volume":"14","author":"Chen","year":"2021","journal-title":"Infect. Drug Resist."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"e19321","DOI":"10.1097\/MD.0000000000019321","article-title":"Efficacy and safety of cefoperazone-sulbactam in empiric therapy for febrile neutropenia: A systemic review and meta-analysis","volume":"99","author":"Lan","year":"2020","journal-title":"Medicine"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1089\/sur.2020.468","article-title":"Clinical Efficacy and Safety of Cefoperazone-Sulbactam in Treatment of Intra-Abdominal Infections: A Systematic Review and Meta-Analysis","volume":"22","author":"Lan","year":"2021","journal-title":"Surg Infect."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"e00023-19","DOI":"10.1128\/AAC.00023-19","article-title":"Randomized Noninferiority Trial of Cefoperazone-Sulbactam versus Cefepime in the Treatment of Hospital-Acquired and Healthcare-Associated Pneumonia","volume":"63","author":"Liu","year":"2019","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.jmii.2018.11.004","article-title":"Recommendations and guidelines for the treatment of pneumonia in Taiwan","volume":"52","author":"Chou","year":"2019","journal-title":"J. Microbiol. Immunol. Infect."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1186\/s13017-017-0141-6","article-title":"The management of intra-abdominal infections from a global perspective: 2017 WSES guidelines for management of intra-abdominal infections","volume":"12","author":"Sartelli","year":"2017","journal-title":"World J. Emerg. Surg."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1016\/j.jinf.2008.04.002","article-title":"Efficacy and safety of high-dose ampicillin\/sulbactam vs. colistin as monotherapy for the treatment of multidrug resistant Acinetobacter baumannii ventilator-associated pneumonia","volume":"56","author":"Betrosian","year":"2008","journal-title":"J. Infect."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1080\/00365540600951184","article-title":"High-dose ampicillin-sulbactam as an alternative treatment of late-onset VAP from multidrug-resistant Acinetobacter baumannii","volume":"39","author":"Betrosian","year":"2007","journal-title":"Scand. J. Infect. Dis."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1002\/pbc.23245","article-title":"Comparison of piperacillin tazobactam and cefoperazone sulbactam monotherapy in treatment of febrile neutropenia","volume":"58","author":"Karaman","year":"2012","journal-title":"Pediatr. Blood Cancer"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"e27266","DOI":"10.1097\/MD.0000000000027266","article-title":"Comparative efficacy and safety of antipseudomonal \u03b2-lactams for pediatric febrile neutropenia: A systematic review and Bayesian network meta-analysis","volume":"100","author":"Tan","year":"2021","journal-title":"Medicine"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"106491","DOI":"10.1016\/j.ijantimicag.2021.106491","article-title":"Clinical effectiveness of cefoperazone-sulbactam vs. piperacillin-tazobactam for the treatment of pneumonia in elderly patients","volume":"59","author":"Huang","year":"2022","journal-title":"Int. J. Antimicrob. Agents"}],"container-title":["Antibiotics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2079-6382\/11\/5\/610\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T23:05:06Z","timestamp":1760137506000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2079-6382\/11\/5\/610"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,30]]},"references-count":20,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2022,5]]}},"alternative-id":["antibiotics11050610"],"URL":"https:\/\/doi.org\/10.3390\/antibiotics11050610","relation":{},"ISSN":["2079-6382"],"issn-type":[{"type":"electronic","value":"2079-6382"}],"subject":[],"published":{"date-parts":[[2022,4,30]]}}}